Navigation Links
Pfizer Launches 'Think Science Now'
Date:6/24/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Ascension Orthopedics Hires Key Senior Executives 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 1FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 2FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 3FDA Advisory Committee Votes in Favor of SAPHRIS 28R 29 28asenapine 29 for Acute Bipolar I Disorder and Acute Schizophrenia 4800 4VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 1VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 2VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE 4799 3Americans Spend Billions on Alternative Medicine 53255 1Americans Spend Billions on Alternative Medicine 53255 2Americans Spend Billions on Alternative Medicine 53255 3
Other Medicine Technology:IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 2IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 3IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 4IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP) 5Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 2Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 3Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 4Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma 5